rel-(3R,4R)-4-(4-hydroxyphenyl)-3-piperidinol | 783291-76-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: rel-(3R,4R)-4-(4-hydroxyphenyl)-3-piperidinol
• 英文别名: (3R,4R)-4-(4-hydroxyphenyl)piperidin-3-ol
• CAS: 783291-76-9
• 化学式: C₁₁H₁₅NO₂
• 分子量: 193.246
• InChiKey: CWQAJUGYGJZUFG-MNOVXSKESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  52.5
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  rel-(3R,4R)-4-(4-hydroxyphenyl)-3-piperidinol 在 sodium tetrahydroborate 、 sodium hydride 、 potassium carbonate 、 三乙胺 、 nickel dichloride 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 94.0h， 生成 (3R,4R)-4-[4-[3-(2-methoxy-benzyloxy)-propoxy]-phenyl]-3-(1,2,3,4-tetrahydro-quinolin-7-ylmethoxy)-piperidine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  Piperidine renin inhibitors: from leads to drug candidates

  摘要：

  Non-peptidomimetic renin inhibitors of the piperidine type represent a novel structural class of compounds potentially free of the drawbacks seen with peptidomimetic compounds so far. Synthetic optimization in two structural series focusing on improvement of potency, as well as on physicochemical properties and metabolic stability, has led to the identification of two candidate compounds 14 and 23. Both display potent and long-lasting blood pressure lowering effects in conscious sodium-depleted marmoset monkeys and double transgenic rats harboring both the human angiotensinogen and the human renin genes. In addition, 14 normalizes albuminuria and kidney tissue damage in these rats when given over a period of 4 weeks. These data suggest that treatment of chronic renal failure patients with a renin inhibitor might result in a significant improvement of the disease status. (C) 2001 Elsevier Science S.A. All rights reserved.

  DOI：

  10.1016/s0014-827x(01)01004-7
• 作为产物：
  描述：

  (3R,4R)-4-(4-benzyloxy-phenyl)-1-((R)-1-phenyl-ethyl)-piperidin-3-ol 在 palladium on activated charcoal 氢气 作用下， 以 甲醇 为溶剂， 反应 15.0h， 生成 rel-(3R,4R)-4-(4-hydroxyphenyl)-3-piperidinol
  参考文献：
  名称：

  Piperidine renin inhibitors: from leads to drug candidates

  摘要：

  Non-peptidomimetic renin inhibitors of the piperidine type represent a novel structural class of compounds potentially free of the drawbacks seen with peptidomimetic compounds so far. Synthetic optimization in two structural series focusing on improvement of potency, as well as on physicochemical properties and metabolic stability, has led to the identification of two candidate compounds 14 and 23. Both display potent and long-lasting blood pressure lowering effects in conscious sodium-depleted marmoset monkeys and double transgenic rats harboring both the human angiotensinogen and the human renin genes. In addition, 14 normalizes albuminuria and kidney tissue damage in these rats when given over a period of 4 weeks. These data suggest that treatment of chronic renal failure patients with a renin inhibitor might result in a significant improvement of the disease status. (C) 2001 Elsevier Science S.A. All rights reserved.

  DOI：

  10.1016/s0014-827x(01)01004-7

文献信息

• Selective NR2B Antagonists
  申请人：Bristol-Myers Squibb Company

  公开号：US20150191452A1

  公开（公告）日：2015-07-09

  The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.

  该披露通常涉及到I式化合物，包括它们的盐，以及使用这些化合物的组合物和方法。这些化合物是NR2B受体的配体，可能对治疗中枢神经系统的各种疾病有用。
• SELECTIVE NR2B ANTAGONISTS
  申请人：Bristol-Myers Squibb Company

  公开号：EP3092224B1

  公开（公告）日：2018-08-22
• THIOPHEN-2-YL-PYRIDIN-2-YL-1H-PYRAZOLE-4-CARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS
  申请人：ADAMS Christopher M.

  公开号：US20170197950A1

  公开（公告）日：2017-07-13

  The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
• US9221796B2
  申请人：——

  公开号：US9221796B2

  公开（公告）日：2015-12-29
• US9765067B2
  申请人：——

  公开号：US9765067B2

  公开（公告）日：2017-09-19